Johanna Snäll1, Jyrki Törnwall2, Anna Liisa Suominen3,4, Hanna Thorén5,6. 1. Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, FI-00029, Helsinki, Finland. johanna.snall@helsinki.fi. 2. Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, FI-00029, Helsinki, Finland. 3. University of Eastern Finland, Institute of Dentistry, Kuopio, Finland. 4. Department of Oral and Maxillofacial Surgery, Kuopio University Hospital, Kuopio, Finland. 5. Department of Oral and Maxillofacial Surgery, Institute of Dentistry, University of Turku, Turku, Finland. 6. Department of Oral and Maxillofacial Diseases, Turku University Hospital, Turku, Finland.
Abstract
PURPOSE: To clarify pre- and postoperative C-reactive protein (CRP) levels in patients with facial fractures and to investigate the influence of perioperatively administered dexamethasone on postoperative CRP levels. PATIENTS AND METHODS: Facial fracture patients were randomized to receive perioperatively a total dose of 30 mg of dexamethasone (Oradexon®), whereas patients in the control group received no glucocorticoid. The analysis included patients who had CRP measured pre- and postoperatively. RESULTS: A total of 73 adult patients with facial fractures were included in the final analysis. Mean CRP level was elevated preoperatively and the level increased further after surgery. However, postoperative CRP rise was significantly impeded by dexamethasone (p < 0.001), regardless of gender, age, treatment delay, site of fracture, surgical approach, and duration of surgery. CRP rise halved on the 1st postoperative day when dexamethasone was used. In addition, dexamethasone resulted in a CRP decrease on the 2nd postoperative day, whereas the CRP rise continued in the control group. CONCLUSIONS:CRP rise is a normal body response after facial fracture and surgery that can be markedly reduced with dexamethasone. CRP changes should be considered with caution if perioperative dexamethasone is used.
RCT Entities:
PURPOSE: To clarify pre- and postoperative C-reactive protein (CRP) levels in patients with facial fractures and to investigate the influence of perioperatively administered dexamethasone on postoperative CRP levels. PATIENTS AND METHODS: Facial fracturepatients were randomized to receive perioperatively a total dose of 30 mg of dexamethasone (Oradexon®), whereas patients in the control group received no glucocorticoid. The analysis included patients who had CRP measured pre- and postoperatively. RESULTS: A total of 73 adult patients with facial fractures were included in the final analysis. Mean CRP level was elevated preoperatively and the level increased further after surgery. However, postoperative CRP rise was significantly impeded by dexamethasone (p < 0.001), regardless of gender, age, treatment delay, site of fracture, surgical approach, and duration of surgery. CRP rise halved on the 1st postoperative day when dexamethasone was used. In addition, dexamethasone resulted in a CRP decrease on the 2nd postoperative day, whereas the CRP rise continued in the control group. CONCLUSIONS:CRP rise is a normal body response after facial fracture and surgery that can be markedly reduced with dexamethasone. CRP changes should be considered with caution if perioperative dexamethasone is used.
Authors: Simone Radtke; Stefan Wüller; Xiang-ping Yang; Barbara E Lippok; Barbara Mütze; Christine Mais; Hildegard Schmitz-Van de Leur; Johannes G Bode; Matthias Gaestel; Peter C Heinrich; Iris Behrmann; Fred Schaper; Heike M Hermanns Journal: J Cell Sci Date: 2010-03-15 Impact factor: 5.285
Authors: Eeva Kormi; Johanna Snäll; Anna-Maria Koivusalo; Anna Liisa Suominen; Hanna Thorén; Jyrki Törnwall Journal: J Oral Maxillofac Surg Date: 2016-09-26 Impact factor: 1.895
Authors: Michael Mihlan; Anna M Blom; Koba Kupreishvili; Nadine Lauer; Kristin Stelzner; Frida Bergström; Hans W M Niessen; Peter F Zipfel Journal: FASEB J Date: 2011-08-19 Impact factor: 5.191
Authors: Gildasio S De Oliveira; Lucas J Santana Castro-Alves; Shireen Ahmad; Mark C Kendall; Robert J McCarthy Journal: Anesth Analg Date: 2012-12-07 Impact factor: 5.108
Authors: Robert Kleemann; Philippe P Gervois; Lars Verschuren; Bart Staels; Hans M G Princen; Teake Kooistra Journal: Blood Date: 2002-08-29 Impact factor: 22.113
Authors: Allan M Golder; Stephen T McSorley; Rachel J Kearns; Donald C McMillan; Paul G Horgan; Campbell S Roxburgh Journal: Ann Med Surg (Lond) Date: 2019-10-11